Announced Sat, 18 Jul · 09:33 IST
USFDA inspection at InvaGen facility ends with 1 Form 483 observation
Regulatory & Legal View source PDF
CIPLA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+1.0%1-day move
₹1419.30
prior close
—
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
————+1.0-0.2-1.7-0.7-0.3—————
Up moveDown movePending
AI summary
Cipla's wholly-owned US subsidiary InvaGen Pharmaceuticals had a routine cGMP inspection by the USFDA at its Central Islip, Long Island facility from 13 to 17 July 2026. The inspection concluded with 1 inspectional observation in Form 483. Cipla will work closely with the USFDA to address it within the stipulated time.
Likely market impact
Single Form 483 observation from a routine USFDA inspection is relatively minor. No Warning Letter or import alert. Usually resolved without material impact.